Publication Details
Abstract
Background: Glycemic control is still the most important aspect of T2DM treatment sodium-glucose cotransporter-2 (SGLT2) inhibitor, empagliflozin, and metformin therapy has been shown to be effective and well tolerated in patients with T2DM and is first of the several recommended treatment options. Since empagliflozin is poorly studied solely or in comparison with metformin, the current study aims at comparing the influence of these drugs on glycemic level individually in patients with type 2 diabetes mellitus (T2DM). Method: The study was a quantitative experimental investigation (cross-sectional study) which contrasted the influence of metformin and empagliflozin on the short-term glycemic level, the metformin group included 30 newly diagnosed type 2 diabetic patients are treated with 1500mg of metformin divided 3 times daily and empagliflozin group includes 30 newly diagnosed type 2 diabetic patients are treated with 10mg of Empagliflozin once time daily). A total of fifty male patients aged (30-70) years were enrolled in this study. This study was performed from may 2022 to August 2022. All patients were already a newly diagnosed as diabetic patients with type 2 according to their medical history of diabetes and the ADA and WHO diagnostic criteria. Blood samples were analyzed for basic and advanced investigations. A complete blood cell count (CBC) was assessed via the URIT-3000Plus automated analyzer electrochemiluminescence (E.C.L.) technology for immunoassay analysis was used for measurement of Lipid profile, Liver function test, Renal function tests, Fasting blood glucose level, Hormones (insulin, TSH) and Hemoglobin A1C (HbA1c) Test. Also SPA antigen Sandwich immunoluminometric assay was used for Measurement of the immunological parameter glutamic acid decarboxylase antibody (GAD65). Results: the results of human samples were indicated that the metformin-treated group was shown a significant difference in the mean level of pre-post glucose test when compared to the empagliflozin-consuming group. The level of glucose was decreased significantly in the group treated with metformin more than in the group treated with empagliflozin, P values were <0.001. Interestingly, the repeated measurements of glucose level also indicated a significant difference, P values were <0.001. In conclusion: Metformin and empagliflozin have been shown through clinical studies an improved in the lowering blood glucose. Both medications were significantly improved glycemic control.